Carl Zeiss Meditec AG (CZMWF)

OTCMKTS · Delayed Price · Currency is USD
27.28
0.00 (0.00%)
At close: Mar 26, 2026
Market Cap2.45B -61.4%
Revenue (ttm)2.59B +5.9%
Net Income141.61M -23.2%
EPS1.64 -21.2%
Shares Outn/a
PE Ratio17.32
Forward PE15.10
Dividendn/a
Ex-Dividend Daten/a
Volume10
Average Volume68
Open27.91
Previous Closen/a
Day's Range27.91 - 27.91
52-Week Range26.42 - 70.88
Beta1.41
RSI35.66
Earnings DateMay 12, 2026

About Carl Zeiss Meditec AG

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and p... [Read more]

Sector Healthcare
Founded 1846
Employees 5,784
Stock Exchange OTCMKTS
Ticker Symbol CZMWF

Financial Performance

In fiscal year 2025, Carl Zeiss Meditec AG's revenue was 2.23 billion, an increase of 7.82% compared to the previous year's 2.07 billion. Earnings were 141.21 million, a decrease of -20.99%.

Financial numbers in EUR Financial Statements

News

Carl Zeiss Meditec AG Completes Acquisition of Dutch Ophthalmic Research Center (D.O.R.C.); Companies Unite to Shape Ophthalmology Market

ZEISS secures regulatory approvals to acquire D.O.R.C.; companies now shift focus to integration implementation, fueling world-class innovation, and driving market expansion strategy for ophthalmic me...

2 years ago - PRNewsWire

Carl Zeiss Meditec AG announces agreement to acquire Dutch Ophthalmic Research Center (D.O.R.C.)

Acquisition will extend the company's leadership in ophthalmic medical devices market and expands its position in the vitreo-retinal surgery segment JENA, Germany , Dec. 15, 2023 /PRNewswire/ -- Carl ...

2 years ago - PRNewsWire